Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator

Biochemical Journal

Volumn 384, Issue 3, 2004, Pages 495-505

  Hu, Youli ^a   González Martínez, David ^a   Kim, Soo Hyun ^a   Bouloux, Pierre Marc Gilles ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anosmin 1; Fibronectin like type III domain; Heparan sulphate; Kallmann's syndrome; Serine protease inhibitor; Whey acidic protein like domain (WAP domain)

Indexed keywords

ACTIVATION ANALYSIS; BIOCHEMISTRY; CATALYST ACTIVITY; CELLS; COMPLEXATION; DISEASE CONTROL; DISEASES; SURFACE PLASMON RESONANCE;

ANOSMIN-1; CELL PROLIFERATION; HEREDITARY DISORDERS; X-LINKED KALLMANN'S SYNDROME (X-KS);

PROTEINS;

ANOSMIN 1; FIBRONECTIN; GENE PRODUCT; HEPARAN SULFATE; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARCINOMA CELL; CELL LINE; CELL LYSATE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KALLMANN SYNDROME; MITOGENESIS; MOLECULAR INTERACTION; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; WHEY ACIDIC PROTEIN LIKE DOMAIN; X CHROMOSOME LINKED DISORDER;

ANIMALS; CATTLE; CELL LINE; CELL PROLIFERATION; CHROMOSOMES, HUMAN, X; DROSOPHILA MELANOGASTER; EXTRACELLULAR MATRIX PROTEINS; GENETIC VECTORS; HEPARIN; HEPARITIN SULFATE; HUMANS; KALLMANN SYNDROME; KINETICS; MULTIPROTEIN COMPLEXES; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE; THROMBIN; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA;

EID: 9244231594     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20041078     Document Type: Article

References (43)

1. Oliveira, L. M., Seminara, S. B., Beranova, M., Hayes, F. J., Valkenburgh, S. B., Schipani, E., Costa, E. M., Latronico, A. C., Crowley, Jr, W. F. and Vallejo, M. (2001) The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J. Clin. Endocrinol. Metab. 86, 1532-1538
2. Quinton, R., Duke, V. M., de Zoysa, P. A., Platts, A. D., Valentine, A., Kendall, B., Pickman, S., Kirk, J. M., Besser, G. M., Jacobs, H. S. and Bouloux, P. M. (1996) The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. J. Clin. Endocrinol. Metab 81, 3010-3017
3. Bulow, H. E., Berry, K. L., Topper, L. H., Peles, E. and Hobert, O. (2002) Heparan sulfate proteoglycan-dependent induction of axon branching and axon misrouting by the Kallmann syndrome gene kal-1. Proc. Natl. Acad. Sci. U.S.A. 99, 6346-6351
4. Rugarli, E. I., Di Schiavi, E., Hilliard, M. A., Arbucci, S., Ghezzi, C., Facciolli, A., Coppola, G., Ballabio, A. and Bazzicalupo, P. (2002) The Kallmann syndrome gene homolog in C. elegans is involved in epidermal morphogenesis and neurite branching. Development 129, 1283-1294
5. Soussi-Yanicostas, N., Faivre-Sarrailh, C., Hardelin, J. P., Levilliers, J., Rougon, G. and Petit, C. (1998) Anosmin-1 underlying the X chromosome-linked Kallmann syndrome is an adhesion molecule that can modulate neurite growth in a cell-type specific manner. J. Cell Sci. 111, 2953-2965
6. MacColl, G., Bouloux, P. and Quinton, R. (2002) Kallmann syndrome: adhesion, afferents, and anosmia. Neuron 34, 675-678
7. Turnbull, J., Powell, A. and Guimond, S. (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 11, 75-82
8. Robertson, A., MacColl, G. S., Nash, J. A., Boehm, M. K., Perkins, S. J. and Bouloux, P. M. (2001) Molecular modelling and experimental studies of mutation and cell-adhesion sites in the fibronectin type III and whey acidic protein domains of human anosmin-1. Biochem. J. 357, 647-659
9. Bulow, H. E. and Hobert, O. (2004) Differential sulfations and epimerization define heparan sulfate specificity in nervous system development. Neuron 41, 723-736
10. Ranganathan, S., Simpson, K. J., Shaw, D. C. and Nicholas, K. R. (1999) The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. J. Mol. Graph. Model. 17, 106-113
11. Schalkwijk, J., Wiedow, O. and Hirose, S. (1999) The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J. 340, 569-577
12. Grutter, M. G., Fendrich, G., Huber, R. and Bode, W. (1988) The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J. 7, 345-351
13. Tsunemi, M., Matsuura, Y., Sakakibara, S. and Katsube, Y. (1996) Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 Å resolution. Biochemistry 35, 11570-11576
14. Larsen, M., Ressler, S. J., Lu, B., Gerdes, M. J., McBride, L., Dang, T. D. and Rowley, D. R. (1998) Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type 'four-disulfide core' domain protein expressed in smooth muscle. J. Biol. Chem. 273, 4574-4584
15. Thompson, K. and Rabinovitch, M. (1996) Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J. Cell. Physiol 166, 495-505
16. Dent, M. A., Sumi, Y., Morris, R. J. and Seeley, P. J. (1993) Urokinase-type plasminogen activator expression by neurons and oligodendrocytes during process outgrowth in developing rat brain. Eur. J. Neurosci. 5, 633-647
17. Dihanich, M., Kaser, M., Reinhard, E., Cunningham, D. and Monard, D. (1991) Prothrombin mRNA is expressed by cells of the nervous system. Neuron 6, 575-581
18. Thewke, D. P. and Seeds, N. W. (1996) Expression of hepatocyte growth factor/scatter factor, its receptor, c-met, and tissue-type plasminogen activator during development of the murine olfactory system. J. Neurosci. 16, 6933-6944
19. Saksela, O. and Holthofer, H. (1987) Plasminogen activators during differentiation of the human kidney. Differentiation 34, 131-138
20. Sumi, Y., Dent, M. A., Owen, D. E., Seeley, P. J. and Morris, R. J. (1992) The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development 116, 625-637
21. Blasi, F. and Carmeliet, P. (2002) uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943
22. Pittman, R. N., Ivins, J. K. and Buettner, H. M. (1989) Neuronal plasminogen activators: cell surface binding sites and involvement in neurite outgrowth. J. Neurosci. 9, 4269-4286
23. Soussi-Yanicostas, N., Hardelin, J. P., Arroyo-Jimenez, M. M., Ardouin, O., Legouis, R., Levilliers, J., Traincard, F., Betton, J. M., Cabanie, L. and Petit, C. (1996) Initial characterization of anosmin-1, a putative extracellular matrix protein synthesized by definite neuronal cell populations in the central nervous system. J. Cell Sci. 109, 1749-1757
24. Rugarli, E. I., Ghezzi, C., Valsecchi, V. and Ballabio, A. (1996) The Kallmann syndrome gene product expressed in COS cells is cleaved on the cell surface to yield a diffusible component. Hum. Mol. Genet. 5, 1109-1115
25. Shriver, Z., Raman, R., Venkataraman, G., Drummond, K., Turnbull, J., Toida, T., Linhardt, R., Biemann, K. and Sasisekharan, R. (2000) Sequencing of 3-0 sulfate containing heparin decasaccharides with a partial antithrombin III binding site. Proc. Natl. Acad. Sci. U.S.A. 97, 10359-10364
26. Andreasen, P. A., Kjoller, L., Christensen, L. and Duffy, M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1-22
27. Sasisekharan, R., Shriver, Z., Venkataraman, G. and Narayanasami, U. (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521-528
28. Herndon, M. E., Stipp, C. S. and Lander, A. D. (1999) Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Glycobiology 9, 143-155
29. Pucci, M., Fibbi, G., Magnelli, L. and Del Rosso, M. (2001) Regulation of urokinase/urokinase receptor interaction by heparin-like glycosaminoglycans. J. Biol. Chem. 276, 4756-4765
30. Esko, J. D. and Lindahl, U. (2001) Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173
31. Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L. and Lose, E. J. (1992) Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8, 365-393
32. Rapraeger, A. C. (1993) The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr. Opin. Cell Biol. 5, 844-853
33. Wight, T. N., Kinsella, M. G. and Qwarnstrom, E. E. (1992) The role of proteoglycans in cell adhesion, migration and proliferation. Curr. Opin. Cell Biol. 4, 793-801
34. Kwan, C. P., Venkataraman, G., Shriver, Z., Raman, R., Liu, D., Qi, Y., Varticovski, L. and Sasisekharan, R. (2001) Probing fibroblast growth factor dimerization and role of heparin-like glycosaminoglycans in modulating dimerization and signaling. J. Biol. Chem. 276, 23421-23429
35. Shriver, Z., Sundaram, M., Venkataraman, G., Fareed, J., Linhardt, R., Biemann, K. and Sasisekharan, R. (2000) Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc. Natl. Acad. Sci. U.S.A. 97, 10365-10370
36. +-ATPase inhibitor (SPAI). Biochem. Biophys. Res. Commun. 172, 42-46
37. Angelloz-Nicoud, P. and Binoux, M. (1995) Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136, 5485-5492
38. Rosini, P., Bonaccorsi, L., Baldi, E., Chiasserini, C., Forti, G., De Chiara, G., Lucibello, M., Mongiat, M., Iozzo, R. V., Garaci, E. et al. (2002) Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 53, 310-321
39. Toba, Y., Horie, M., Sango, K., Tokashiki, A., Matsui, F., Oohira, A. and Kawano, H. (2002) Expression and immunohistochemical localization of heparan sulphate proteoglycan N-syndecan in the migratory pathway from the rat olfactory placode. Eur. J. Neurosci. 15, 1461-1473
40. Grisaru, S. and Rosenblum, N. D. (2001) Glypicans and the biology of renal malformations. Pediatr. Nephrol. 16, 302-306
41. Dode, C., Levilliers, J., Dupont, J. M., De Paepe, A., Le Du, N., Soussi-Yanicostas, N., Coimbra, R. S., Delmaghani, S., Compain-Nouaille, S., Baverel, F. et al. (2003) Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat. Genet. 33, 463-465
42. Mochizuki, Y., Tsuda, S., Kanetake, H. and Kanda, S. (2002) Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Oncogene 21, 7027-7033
43. Padro, T., Mesters, R. M., Dankbar, B., Hintelmann, H., Bieker, R., Kiehl, M., Berdel, W. E. and Kienast, J. (2002) The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells. J. Cell Sci. 115, 1961-1971